

Miriam Toledo Soler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3033405/publications.pdf>

Version: 2024-02-01

33
papers

1,505
citations

331670

21
h-index

414414

32
g-index

33
all docs

33
docs citations

33
times ranked

2202
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of cytokines in cancer cachexia. <i>Current Opinion in Supportive and Palliative Care</i> , 2009, 3, 263-268.	1.3	162
2	The cachexia score (CASCO): a new tool for staging cachectic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 87-93.	7.3	138
3	Autophagy Regulates the Liver Clock and Glucose Metabolism by Degrading CRY1. <i>Cell Metabolism</i> , 2018, 28, 268-281.e4.	16.2	124
4	Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012, 3, 37-43.	7.3	115
5	System-wide Benefits of Intermeal Fasting by Autophagy. <i>Cell Metabolism</i> , 2017, 26, 856-871.e5.	16.2	104
6	Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency?. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 2770-2778.	2.4	83
7	Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. <i>Oncotarget</i> , 2015, 6, 43202-43215.	1.8	78
8	Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 95-104.	7.3	72
9	Cachexia: a problem of energetic inefficiency. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014, 5, 279-286.	7.3	72
10	Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β agonist. <i>International Journal of Cancer</i> , 2016, 138, 2021-2029.	5.1	55
11	A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 48-59.	7.3	45
12	Complement C3 and Autophagy Keep the β Cell Alive. <i>Cell Metabolism</i> , 2019, 29, 4-6.	16.2	45
13	Formoterol in the treatment of experimental cancer cachexia: effects on heart function. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014, 5, 315-320.	7.3	44
14	Differences in food intake of tumour-bearing cachectic mice are associated with hypothalamic serotonin signalling. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015, 6, 84-94.	7.3	38
15	l-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer. <i>Clinical Nutrition</i> , 2012, 31, 889-895.	5.0	37
16	Cancer cachexia: physical activity and muscle force in tumour-bearing rats. <i>Oncology Reports</i> , 2011, 25, 189-93.	2.6	33
17	Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats. <i>Oncology Letters</i> , 2012, 3, 185-189.	1.8	31
18	Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia. <i>Clinical Nutrition</i> , 2010, 29, 733-737.	5.0	27

#	ARTICLE	IF	CITATIONS
19	Interleukin-15 Affects Differentiation and Apoptosis in Adipocytes: Implications in Obesity. <i>Lipids</i> , 2011, 46, 1033-1042.	1.7	25
20	Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3. <i>PLoS ONE</i> , 2014, 9, e113931.	2.5	24
21	Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration?. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 57-62.	7.3	22
22	A differential pattern of gene expression in skeletal muscle of tumour-bearing rats reveals dysregulation of excitation-contraction coupling together with additional muscle alterations. <i>Muscle and Nerve</i> , 2014, 49, 233-248.	2.2	20
23	Theophylline is able to partially revert cachexia in tumour-bearing rats. <i>Nutrition and Metabolism</i> , 2012, 9, 76.	3.0	18
24	Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. <i>Journal of Lipid Research</i> , 2013, 54, 3045-3051.	4.2	17
25	A Rat Immobilization Model Based on Cage Volume Reduction: A Physiological Model for Bed Rest?. <i>Frontiers in Physiology</i> , 2017, 8, 184.	2.8	17
26	Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 731-735.	1.8	16
27	Food craving-like episodes during pregnancy are mediated by accumbal dopaminergic circuits. <i>Nature Metabolism</i> , 2022, 4, 424-434.	11.9	13
28	Nutraceutical inhibition of muscle proteolysis: A role of diallyl sulphide in the treatment of muscle wasting. <i>Clinical Nutrition</i> , 2011, 30, 33-37.	5.0	10
29	The animal cachexia score (ACASCO). <i>Animal Models and Experimental Medicine</i> , 2019, 2, 201-209.	3.3	9
30	Effects of formoterol on protein metabolism in myotubes during hyperthermia. <i>Muscle and Nerve</i> , 2011, 43, 268-273.	2.2	5
31	Megestrol acetate treatment influences tissue amino acid uptake and incorporation during cancer cachexia. <i>E-SPEN Journal</i> , 2012, 7, e135-e138.	0.5	3
32	Immobilization in diabetic rats results in altered glucose tolerance A model of reduced locomotion/activity in diabetes. <i>JCSM Rapid Communications</i> , 2018, 1, 1-15.	1.6	3
33	Pro-Inflammatory Cytokines and their Actions on the Metabolic Disturbances Associated with Cancer: Implications in Cachexia. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2011, 10, 275-280.	1.1	0